Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
PRINCETON, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and...
-
ZUSDURI™ generated revenue of $29.2 million in Q1 2026, representing 109% quarter-over-quarter growth, reflecting broader utilization with the permanent J Code effective January 1, 2026JELMYTO...
-
PRINCETON, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and...
-
UroGen Launches LG-UTUC Luminaries Initiative recognizing clinicians and institutions working to achieve excellence in LG-UTUC care.
-
UroGen announces that the pivotal ENVISION 24 mo. Duration of Response date has been published online in The Journal of Urology.
-
BCAN Launches News Faces of Bladder Cancer Report based on a survey of 1,100 patients.
-
PRINCETON, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and...
-
Commercial launch is on-track for ZUSDURI™, the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC); net sales...
-
Opportunistic refinancing meaningfully reduces cost of capital with 8.25% fixed interest rate and extends amortization period to Q1 2030 $200 million funded at closing to refinance the existing $125...
-
New data from the pivotal ENVISION trial with ZUSDURI shows durable complete responses across EORTC risk groups. Data presented at ASCO GU 2026.